SIMPULAN DAN SARAN
6.1 Simpulan
6.1.2 Reseptor hormonal negatif ganda (ER- dan PR -) merupakan kejadian yang terbanyak dengan 30 kasus (52,6%) diikuti dengan reseptor hormonal ganda positif (ER+ dan PR +) 18 kasus (31,5%).
6.1.3 Over ekspresi Ki67 pada pasien kanker payudara di RSUP Haji Adam Malik 24 kasus (42,2%).
6.1.4 Low ekspresi Ki67 pada pasien kanker payudara di RSUP Haji Adam Malik 33 kasus (57,8%).
6.1.5 Pada pasien menopause low ekspresi Ki 67 pada pasien pre menopause, perimenopause dan menopause yang terbanyak masing masing sebanyak 15 dari 25 kasus pre menopause, 8 dari 14 kasus perimenopause dan 11 dari 18 kasus menopause.
6.2 Saran
6.2.1 Perlunya dilakukan penelitian untuk melihat hubungan ekspresi ER, PR dan Ki67 dengan status menstruasi pada penderita kanker payudara di RSUP H. Adam Malik.
38
DAFTAR PUSTAKA
1. Aleskandarany MA, Green AR, Benhasouna AA, Barros FF, Neal K ,Reis JS-Filho,et al (2011).Prognostic value of proliferation assay in theluminal, HER2-positive, and triple negativebiologic classes of breast cancer. Breast-Cancer-Research.p1-11
2. American Cancer Society, (2013). Breast Cancer Fact & Figures 2013-2014.
3. Ahmed HG, Al-Adhraei MA, Al-Thobhani AK. (2011) Correlation of Hormone Receptors (ER and PR), Her2/neu and p53 Expression in Breast Ductal Carcinoma Among Yemeni Women. The Open Cancer Immunology Jounal.
4. Asako O, Takaharab S, Sumiyoshia K, Yamamotoa H, Kawaic J andShibaa E (2013) Relationship between intrinsic subtypes and tumor responses to neoadjuvant chemotherapy in patients with locally advanced breast cancer.Breast Disease 34 (2012/2013) 9-17
5. Baziad A. (2008). Endokrinologi Ginekologi edisi ketiga: Menopause. Penerbit Media Aesculapius Fakultas Kedokteran Universitas Indonesia. Hal.115-117.
6. Brufsky AM, (2011).Understanding the estrogen receptor signaling pathway :focus on current endocrine agents for breast cancer in postmenopausal women.(review). Community Oncology;8:343-52.
7. Byrd DR, Edge SB (2010) AJCC Breast Cancer Staging Manual, 7th Ed. New York. NY: Springer.p347-76
8. Cheang MCV, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al.( 2009). Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. University of British Columbia
9. Departemen Kesehatan Republik Indonesia, (2013) Pemerintah Targetkan 80% Perempuan dapat Deteksi Dini Kanker Payudara dan Kanker Serviks.
10.Direktorat Jenderal PP & PL Kementerian Kesehatan, 2013. Panduan Memperingati Hari kanker sedunia di Indonesia Tahun 2013.
11.Devita VT, Hellman S, Rosenberg SA.(2008) Penyunting. Cancer Principles and practice of oncology. Edisi ke-8. Philadelphia. Lippincott william & Wilkins.
12.Dunwald LK, Rossing MA, Li CI.(2007) Breast Cancer Researh. Hormon receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.
13.Ellis IO, Schinitt SJ, Satre GX, (2003) Invasive Breast Carcinoma in World Health Organization Classification of Tumours Pathology & Genetics Tumours of Breast and Female Genital Organs. IARC; 13-59
14.Giuseppe V, Regan MM, Mastropasqua MG, Maiorano E, Colleoni M,Price KN et al (2008). Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst. 100:207-212 15.GLOBOCAN, (2008) Breast Cancer Incidence and Mortality Worldwide in 2008
Summary.
16.Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, senn HJ (2009)Thresholds for threapies: hihglights of the St Gallen International Expert Consensus on the primary therapy of early brast cancer. Annal Oncol ;20:1319-29
17.Haroon, Saroona., Hashmi, Atif Ali., Khurshid, Amna., Kanpurwala, Muhammad Adnan., Mutjuba, Shafaq., Malik, Babar., et al, (2013) Ki-67 Index in Breast Cancer: Correlation with Other Prognostic Markers and Potential in Pakistani Patients. Asian Pacific Journal of Cancer Prevention 14: 4353-4357.
18.Inwald, EC., Klinkhammer-Schalke, M., Hofstadter, F., Zeman, F., Koller, M., Gertstenhauer, M., et al, (2013) Ki-67 Is A Prognostic Parameter In Breast Cancer Patients: Results of A Large Population-Based Cohort of A Cancer Registry. Breast Cancer Res Treat 139: 539-552.
19.Jeong S, et al. (2011). Hormone Receptor Status Rather Than HER2 Status is Significantly Associated with Increased Ki-67 and p53 Expression in Triple-negative Breast Carcinomas, and High Expression of Ki-67 but Not p53 is Significantly Associated with Axillary Nodal Metastasis in Triple-negative and High-Grade Non-Triple-Negative Breast Carcinomas. Am J ClinPathol. 135:230-237.
20.Jonat W, Arnold N. Is Ki 67 the labelling index ready for clinical use? Ann Oncol (2011) 22:500-2. doi: 10.1093/annoc/mdq732
40
21.Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH et al (2011) Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different respons and prognosis. Breast Cancer Res; 13: R22
22.Lari SA and Kuerer HM, (2011) Review: Biological Markers in DCIS and Risk of Breast Recurrence: A Systemetic Review. Journal of Cancer 2; 232-61
23.Levin ER,(2005), Integration of Extranuclear and Nuclear Actions of Estrogen. Mol. Endrocrinologi. 19(8):p1951-9
24.Payne SJL, Bowen RL, Jones JL & Wells CA. (2008) Predictive markers in breast cancer- the present histopatholgy;52: 82-90
25.Pabian CJ, Kivoler BF (2005). Selective Estrogen Receptor Modulator for Primary Prevention of Breat Cancer. J. Clinical Oncology.p.1644-55
26.Pasaribu ET, Issakh B ,(2014) Breast Cancer Trends in Semarang : an Analysis of Histological and Molecular Types.
27.Ramli, Muchlis, (1995) Kanker Payudara. Dalam: Kumpulan Kuliah Ilmu Bedah. Jakarta: Binarupa Aksara, 342-364.
28.Robin JL., Salter, Janine., A Hern, Roger., Nerurkar, Ash., Parton, Marina., Reis-Filho, orge S., et al, (2010) Relationship between oestrogen receptor status and proliferationin predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 119:315-323
29.Rosai J. (2004). Breast. In Rosai and Aekerman’s Surgical Pathology, 9th Ed. Philadelphia: Elsevier,p.1763-1877
30.Rosa FE, Caldeira JRF, Felipes J, Bertonha FB, Quevedo FC, Domingues MAC et al
(2007) Evaluation of Estrogen Receptor α and β and Progesteron Receptor Expression and
Correlation with Clinicopathologic Factors and Proliferative Marker Ki67 in Breast Cancer. Human Pathology. Elsevier.p. 720-730
31.Rumah Sakit Umum Pendidikan H.Adam Malik Medan, (2012) Data Kasus Keganasan Payudara 2008-2011. [Unpublished].
32.Suyatno, Pasribu ET, (2014) Bedah Onkologi; Diagnosis dan terapi, edisi ke-2. Seagung Seto. Jakarta.
33.Shanaz N. Profil Hormonal Reseptor pada Pemeriksaan Immunohistokimia pada Pasien Kanker Payudara di RSUD dr. Soetomo pada tahun (2009). Fakultas Kedokteran Universitas Airlangga. Surabaya 2010
34.Taneja P, Maglic D, Kai F, Zhu S, Kendig RD,Fry EA, Inoue K. (2010). Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. Clinical Medicine Insights. 4:15-34
35.Tan, P.H., Bay, B.H., Yip, G., Selvarajan, S., Tan, P., Wu, J., Lee, C.H., Li, K.B. (2005) Immunohistochemical Detection Of KI 67 In Breast Cancer CorelattesWith Transcriptional Regulation Of Genes Related To Apoptosis And CellDeath. Modern Pathology,18:374- 381.
36.Urruticoechea, U., Smith, I.E., Dowsett, M. (2005). Proliferation Marker Ki-67 inEarly Breast Cancer. J ClinOncol. 23:7212 –7220.
37.Yanger JD, Davidson NE.(2006). Mechanisms of disease, Estrogen Carcinogenesis in Breast Cancer. New England Journal of Medicinen; 354:270-82
38.Yerushalmi, R., Woods, R., Ravdin, PM., Hayes, MM. and Gelmon, KA., (2010). Ki67 in Breast Cancer : Prognostic and Predictive Potential. Lancet Oncol, 11: 174-183.
39.Weigel MT and Dowsett M, (2010) Review; Current and emerging biomarkers in breast cancer: prognosis and prediction; Endocrine- Related Cancer .17:R245-R262
40.Weisner, F.G., Magener, A., Fasching, P.A. (2009) KI 67 As a PrognosticMolecular Marker In Routine Clinical Use In Breast Cancer Patients. TheBreast, 18:135–141.
41.WHO, 2013. Breast Cancer: Prevention and Control.
42.Zhang MH, Man HT, Zhao, Dong N and Ma SL, (2013) Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).Biomedical Reports; 2:41-52
42
Lampiran 1 Peneliti
Susunan Peneliti
Nama Lengkap :dr. Dippan Hutapea
Pangkat/Gol/NIP :Penata/III-C/ 19780914200604 1 018
Jabatan Fungsional :PPDS Ilmu Bedah
Fakultas : Kedokteran
Perguruan Tinggi : Universitas Sumatera Utara
Pembimbing I :
Nama Lengkap :dr.Emir Taris Pasaribu SpB (K)Onk
Pangkat/Gol/NIP : Pembina Utama Madya/IV-D/19520302198002 1 001 Jabatan Fungsional : Kepala Departemen Ilmu Bedah FK USU –RSUP HAM
Fakultas : Kedokteran
Perguruan Tinggi : Universitas Sumatera Utara
Bidang Keahlian : Ilmu Bedah Onkologi
Pembimbing II :
Nama Lengkap : dr. Suyatno, SpB (K)Onk
Pangkat/Gol/NIP : Pembina Utama Muda/IV-B/196806081999031010 Jabatan Fungsional : Staff Pengajar Sub Bagian Bedah Onkologi FK USU
Fakultas : Kedokteran
Perguruan Tinggi : Universitas Sumatera Utara
Bidang Keahlian : Ilmu Bedah Onkologi
Lampiran 2 Rencana Anggaran Penelitian
No Uraian Jumlah
1 Honorarium Rp.2 .000.000,-
2 Fotocopy kuesioner, dll ( 800 lbr x Rp. 200 ) Rp. 1.600.000,- 3 Pembuatan Proposal dan Laporan Penelitian Rp. 1.000.000,- 4 Penggandaan Proposal dan Laporan Penelitian Rp. 1.600.000,-
Total Rp. 6.200.000,-
Sumber dana : dana pribadi peneliti.
Lampiran 3
44 Jadwal Penelitian
MARET 2014 APRIL 2014 MEI- 2014
PERSIAPAN PELAKSANAAN PENYUSUNAN LAPORAN PENGGANDAAN LAPORAN